Cassone, Giulia
 Distribuzione geografica
Continente #
NA - Nord America 10.054
AS - Asia 5.964
EU - Europa 4.518
SA - Sud America 920
AF - Africa 163
OC - Oceania 85
Continente sconosciuto - Info sul continente non disponibili 6
Totale 21.710
Nazione #
US - Stati Uniti d'America 9.739
SG - Singapore 1.817
CN - Cina 1.499
IT - Italia 1.328
GB - Regno Unito 955
BR - Brasile 652
HK - Hong Kong 651
VN - Vietnam 607
SE - Svezia 467
DE - Germania 318
FI - Finlandia 309
BD - Bangladesh 253
FR - Francia 239
RU - Federazione Russa 222
KR - Corea 199
CA - Canada 165
JP - Giappone 160
TR - Turchia 154
IN - India 151
ID - Indonesia 146
UA - Ucraina 117
IE - Irlanda 109
AR - Argentina 97
MX - Messico 94
NL - Olanda 79
AU - Australia 75
BG - Bulgaria 72
PK - Pakistan 56
IQ - Iraq 53
TN - Tunisia 51
PL - Polonia 48
LT - Lituania 45
ZA - Sudafrica 40
CL - Cile 34
EC - Ecuador 34
ES - Italia 34
MY - Malesia 34
CO - Colombia 33
AT - Austria 26
PE - Perù 24
PT - Portogallo 24
PH - Filippine 21
AE - Emirati Arabi Uniti 20
HU - Ungheria 20
SA - Arabia Saudita 20
VE - Venezuela 20
JO - Giordania 17
EG - Egitto 15
NP - Nepal 15
BZ - Belize 14
KE - Kenya 14
MA - Marocco 14
BE - Belgio 13
DK - Danimarca 12
DZ - Algeria 12
IR - Iran 12
RS - Serbia 11
CH - Svizzera 10
NZ - Nuova Zelanda 10
RO - Romania 10
PY - Paraguay 9
TW - Taiwan 9
UZ - Uzbekistan 9
BO - Bolivia 8
TH - Thailandia 8
DO - Repubblica Dominicana 7
LB - Libano 7
LV - Lettonia 7
CZ - Repubblica Ceca 6
HN - Honduras 6
JM - Giamaica 6
OM - Oman 6
UY - Uruguay 6
AZ - Azerbaigian 5
BY - Bielorussia 5
CY - Cipro 5
GR - Grecia 5
HR - Croazia 5
IL - Israele 5
NI - Nicaragua 5
EU - Europa 4
GT - Guatemala 4
LU - Lussemburgo 4
MD - Moldavia 4
MU - Mauritius 4
TT - Trinidad e Tobago 4
CR - Costa Rica 3
EE - Estonia 3
GY - Guiana 3
KG - Kirghizistan 3
KH - Cambogia 3
KW - Kuwait 3
KZ - Kazakistan 3
PA - Panama 3
PS - Palestinian Territory 3
SN - Senegal 3
SY - Repubblica araba siriana 3
AL - Albania 2
BA - Bosnia-Erzegovina 2
BS - Bahamas 2
Totale 21.682
Città #
Santa Clara 1.296
Singapore 1.154
Ashburn 1.040
Fairfield 853
Hong Kong 628
Chandler 507
San Jose 496
Hefei 464
Southend 451
Woodbridge 341
Houston 293
Seattle 278
Council Bluffs 275
Nyköping 264
London 263
Wilmington 263
Helsinki 261
Cambridge 240
Beijing 231
Ann Arbor 215
The Dalles 214
Los Angeles 202
New York 183
Ho Chi Minh City 182
Seoul 169
Jacksonville 143
Hanoi 136
Milan 131
Dallas 124
Modena 123
Chicago 110
Dearborn 110
Jakarta 105
San Diego 97
Shanghai 89
Moscow 79
Dublin 76
Rome 74
Buffalo 73
Lauterbourg 71
Sofia 70
Princeton 68
São Paulo 65
Redwood City 64
Tokyo 60
Orem 59
Munich 56
Bologna 50
Perth 47
Salt Lake City 47
Frankfurt am Main 42
Izmir 41
Bremen 39
Montreal 39
Boardman 38
Eugene 36
Da Nang 35
Columbus 34
Mexico City 34
Manchester 33
Toronto 33
Elk Grove Village 29
Nuremberg 29
Kent 27
San Francisco 27
Warsaw 27
Chennai 26
Brooklyn 25
Falls Church 25
Haiphong 25
Mumbai 24
Atlanta 23
Boston 23
Ankara 22
Bari 22
Baghdad 21
Istanbul 21
Redondo Beach 21
Rio de Janeiro 21
Santiago 21
Amsterdam 20
Naples 20
Phoenix 20
Paris 19
Turku 19
Dong Ket 18
Johannesburg 18
Guangzhou 17
Catania 16
Denver 16
Ottawa 16
Quito 16
Stockholm 16
Bogotá 15
Brasília 15
Buenos Aires 15
Las Vegas 15
Amman 14
Belize City 14
Lappeenranta 14
Totale 14.086
Nome #
Epidemiology and management of interstitial lung disease in ANCA-associated vasculitis 1.369
Analysis of pulmonary sounds for the diagnosis of interstitial lung diseases secondary to rheumatoid arthritis 416
Diagnostic accuracy of a velcro sound detector (VECTOR) for interstitial lung disease in rheumatoid arthritis patients: The InSPIRAtE validation study (INterStitial pneumonia in rheumatoid ArThritis with an electronic device) 408
Carotidynia Possibly due to Localized Vasculitis in a Patient with Latent Mycobacterium tuberculosis Infection. 349
NEW PERSPECTIVES IN DIAGNOSIS OF INTERSTITIAL LUNG DISEASE RELATED TO RHEUMATOID ARTHRITIS. VALIDATION STUDY OF AN ELECTRONIC STETHOSCOPE AND AD HOC SOFTWARE FOR DETECTION OF PULMONARY CRACKLES 349
Combination Therapy with Nintedanib and Sarilumab for the Management of Rheumatoid Arthritis Related Interstitial Lung Disease 348
INTERSTITIAL LUNG DISEASE RELATED TO RHEUMATOID ARTHRITIS. WHAT DO WE DON’T KNOW? THE LIRA STUDY (LUNG INVOLVEMENT IN RHEUMATOID ARTHRITIS) 341
Acute exacerbation of interstitial lung diseases secondary to systemic rheumatic diseases: A prospective study and review of the literature 327
Serum 25-OH vitamin D levels in systemic sclerosis: analysis of 140 patients and review of the literature 325
Gynaecological Screening for Cervical and Vulvar Malignancies in a Cohort of Systemic Sclerosis Patients: Our Experience and Review of the Literature 319
Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: results from the GISEA register 318
Prevalence and characterization of non-sicca onset primary Sjögren syndrome with interstitial lung involvement 313
Nailfold capillaroscopic changes in dermatomyositis and polymyositis 308
Caratteristiche cliniche e nuovi orizzonti diagnostico-terapeutici delle vasculiti dei grandi vasi e della interstiziopatia polmonare secondaria ad artrite reumatoide. 306
Safety of Abatacept in Italian Patients with Rheumatoid Arthritis and Interstitial Lung Disease: A Multicenter Retrospective Study 302
COST ANALYSIS RELATED TO SUBCUTANEOUS IMMUNOGLOBULINS IN PATIENTS WITH INFLAMMATORY MYOPATHIES AND IMMUNE-MEDIATED CHRONIC NEUROPATHIES. RESULTS OF AN OPEN LABEL STUDY 296
Interstitial pneumonia with autoimmune features: A single center prospective follow-up study 292
Efficacy and safety of mycophenolate mofetil in the treatment of rheumatic disease-related interstitial lung disease: a narrative review 292
High-dose glucocorticoids pulse-Therapy for beta-coronaviridae pneumonia: A systematic literature review and case-series of coronavirus disease-2019 289
AB1157 VALIDATION OF VECTOR (VELCRO CRACKLES DETECTOR) FOR THE DIAGNOSIS OF INTERSTITIAL LUNG DISEASE IN PATIENTS WITH CONNECTIVE TISSUE DISEASES 285
The impact of chest CT body composition parameters on clinical outcomes in COVID-19 patients 277
Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicenter retrospective study 261
Measuring microangiopathy abnormalities in systemic sclerosis patients: the role of capillaroscopy-based scoring models 259
Therapeutic Options for the Treatment of Interstitial Lung Disease Related to Connective Tissue Diseases. A Narrative Review 258
[18F]fluorodeoxyglucose positron emission tomography imaging in a case of relapsing polychondritis 257
INTERSTITIAL LUNG DISEASE IS ASSOCIATED TO INFECTIONS OF LOWER RESPIRATORY TRACT IN IMMUNOCOMPROMISED RHEUMATOID ARTHRITIS PATIENTS 252
Acute-phase reactants during tocilizumab therapy for severe COVID-19 pneumonia 249
AB0472 PRIMARY SJOGREN SYNDROME ASSOCIATED INTERSTITIAL LUNG DISEASE: FEATURES, TREATMENT AND OUTCOME OF A MONOCENTRIC COHORT 244
Classification of pulmonary sounds through deep learning for the diagnosis of interstitial lung diseases secondary to connective tissue diseases 241
Nailfold Capillaroscopy Characteristics of Antisynthetase Syndrome and Possible Clinical Associations: Results of a Multicenter International Study 240
Factors Predicting Early Failure of Etanercept in Rheumatoid Arthritis: An Analysis From the Gruppo Italiano di Studio sulla Early Arthritis (Italian Group for the Study of Early Arthritis) Registry 240
Neurologic Complications Associated with Sjögren's Disease: Case Reports and Modern Pathogenic Dilemma 239
Efficacy and safety of rituximab in the treatment of connective tissue disease-related interstitial lung disease 230
Interstitial lung disease is associated to infections of lower respiratory tract in immunocompromised rheumatoid arthritis patients 229
PAP-TEST FEATURES IN A COHORT OF SYSTEMIC SCLEROSIS PATIENTS 228
Nailfold videocapillaroscopy in antisynthetase syndrome 227
Severe alopecia complicating systemic sclerosis 226
Rituximab therapy for primary central nervous system vasculitis: A 6 patient experience and review of the literature 223
Erratum: Acute exacerbation of interstitial lung diseases secondary to systemic rheumatic diseases: A prospective study and review of the literature (Journal of Thoracic Disease (2019) 11 (1621-1628) DOI: 10.21037/jtd.2019.03.28) 220
Arthritis in Systemic Lupus Erythematosus: From 2022 International GISEA/OEG Symposium 214
Tocilizumab for the treatment of patients with rheumatoid arthritis and interstitial lung diseases: a case series 209
Age at diagnosis influences the clinical phenotype, treatment strategies and outcomes in patients with giant cell arteritis: results from the observational GCAGE study on a large cohort of 1004 patients 208
CHARACTERIZATION OF ANTI-MPO POSITIVE INTERSTITIAL LUNG DISEASE. CLINICAL-SEROLOGIC AND RADIOLOGIC FEATURES AND SURVIVAL 205
Usefulness of digital velcro crackles detection in identification of interstitial lung disease in patients with connective tissue diseases 205
VECTOR: An algorithm for the detection of COVID-19 pneumonia from velcro-like lung sounds 204
FRI0613 THERAPEUTIC STRATEGIES AND SURVIVAL IN PATIENTS WITH INTERSTITIAL PNEUMONIA WITH AUTOIMMUNE FEATURES 203
Pirfenidone for the treatment of interstitial lung disease associated to rheumatoid arthritis: a new scenario is coming? 200
Human Dental Pulp Stem Cells Modulate Cytokine Production in vitro by Peripheral Blood Mononuclear Cells From Coronavirus Disease 2019 Patients 198
Tofacitinib for the Treatment of Severe Interstitial Lung Disease Related to Rheumatoid Arthritis 195
Granulomatosis with polyangiitis presenting as a renal mass successfully treated with rituximab 193
Treatment with Rituximab in Systemic Sclerosis Patients: Our Experience in a Pilot Clinical Trial 189
Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lights and Shadows 186
Susceptibility to COVID-19 in Patients Treated With Antimalarials: A Population-Based Study in Emilia-Romagna, Northern Italy 185
The rediscovery of hydroxychloroquine in allergic diseases in the covid-19 era 181
EVALUATION OF INTERNAL CONSISTENCY, FEASIBILITY, AND RELIABILITY OF THE ITALIAN VERSION OF ANCA-ASSOCIATED VASCULITIS PATIENT-REPORTED OUTCOME (AAV-PRO_ITA) QUESTIONNAIRE: PRELIMINARY RESULTS FROM A MULTICENTER STUDY ON A LARGE COHORT OF ITALIAN PATIENTS 180
Diagnosis, Clinical Features and Management of Interstitial Lung Diseases in Rheumatic Disorders: Still a Long Journey 179
EFFICACY OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS TREATMENTS ACCORDING TO THE TYPE OF MANIFESTATIONS BASED ON ANALYSIS OF 636 PATIENTS 176
NAILFOLD CAPILLAROSCOPIC ALTERATIONS IN DERMATOMYOSITIS AND POLYMYOSITIS 175
Axial Spondyloarthritis: Reshape the Future—From the “2022 GISEA International Symposium” 174
Fibrosing interstitial lung disease in primary Sjogren syndrome 172
Treatment of giant cell arteritis with ultra-short glucocorticoids and tocilizumab: results from the extension of the TOPAZIO study 171
Interstitial pneumonia with autoimmune features: Why rheumatologist–pulmonologist collaboration is essential 169
Significance of PR3-ANCA positivity in eosinophilic granulomatosis with polyangiitis (Churg-Strauss) 168
Lung involvement in systemic sclerosis: role of high resolution computed tomography and its relationship with other pulmonary and clinico-serological features. 164
Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: A population-based study 161
117. PREDICTION OF LONG-TERM EVOLUTIONARY PROFILES IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (CHURG– STRAUSS) BASED ON BASELINE AND FOLLOW-UP CHARACTERISTICS 159
354. EFFICACY OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS TREATMENTS ACCORDING TO THE TYPE OF MANIFESTATIONS BASED ON ANALYSIS OF 636 PATIENTS 156
Effects in soluble immune checkpoints induced by Tocilizumab monotherapy after ultra-short-term glucocorticoids in large vessel – giant cell arteritis patients 155
Pathogenesis and treatment of idiopathic and rheumatoid arthritis-related interstitial pneumonia. The possible lesson from COVID-19 pneumonia 155
Tocilizumab or glucocorticoids treatment for patients with SARS-CoV-2 pneumonia: An observational study 154
CLINICAL OUTCOMES OF TREATMENT WITH GOLIMUMAB IN SEROPOSITIVE AND SERONEGATIVE RHEUMATOID ARTHRITIS PATIENTS IN REAL-LIFE SETTINGS. DATA FROM ITALIAN REGISTER GISEA 153
Interstitial lung disease and anti-myeloperoxidase antibodies: not a simple association 153
JANUS KINASES INHIBITORS IN CLINICAL PRACTICE IN ITALY. RESULTS FROM A SINGLE CENTER EXPERIENCE 150
Predictive factors of clinical outcomes in patients with COVID-19 treated with tocilizumab: A monocentric retrospective analysis 145
Rheumatoid arthritis related interstitial lung disease 144
Pneumopathie interstitielle fibrosante dans le syndrome de Gougerot-Sjögren primitif 144
Interstitial lung disease in microscopic polyangiitis and granulomatosis with polyangiitis: demographic, clinical, serological and radiological features of an Italian cohort from the Italian Society for Rheumatology 143
Fibrosing Progressive Interstitial Lung Disease in Rheumatoid Arthritis: A Multicentre Italian Study 143
Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome) 142
Erratum to: Prevalence and characterization of non-sicca onset primary Sjögren syndrome with interstitial lung involvement (Clinical Rheumatology, (2017), 36, 6, (1261-1268), 10.1007/s10067-017-3601-1) 141
Treatment of giant cell arteritis with ultra-short glucocorticoids and tocilizumab: the role of imaging in a prospective observational study 135
Granuloma annulare as a possible new adverse effect of topiramate 133
Reactive Granulomatous Dermatitis during Anti-TNF Therapy: A Case Report and Review of the Literature 133
Validation of the Italian version of the ANCA-associated vasculitis patient-reported outcome (AAV-PRO) questionnaire 132
SAT0470 Pap-Test Features in a Cohort of Systemic Sclerosis Patients 132
Trattamento con Tocilizumab in monoterapia dopo trattamento con glucocorticoidi per breve periodo in pazienti con arterite a cellule giganti con coinvolgimento dei grandi vasi: effetti sui checkpoint immunitari solubili 130
Therapeutic Strategies and Survival in Patients with Interstitial Pneumonia with Autoimmune Features 129
FRI0212 THE ROLE OF AGE ON THE CLINICAL PRESENTATION AND RELAPSE RATES IN A LARGE COHORT OF 720 PATIENTS WITH GIANT CELL ARTERITIS 127
POS1053 PREVALENCE OF FIBROSING PROGRESSIVE INTERSTITIAL LUNG DISEASE IN RHEUMATOID ARTHRITIS PATIENTS 121
Prevalence of Progressive Fibrosing Interstitial Lung Disease in Patients with Primary Sjogren Syndrome 119
Pulmonary Progressive Fibrosis in Rheumatoid Arthritis and Primary Sjogren Syndrome: Similarities and Differences 118
From Bench to Bedside in Rheumatoid Arthritis from the “2022 GISEA International Symposium” 112
NAILFOLD CAPILLAROSCOPY IN ANTISYNTHETASE SYNDROME (NASCAR): RESULTS OF A MULTICENTER, INTERNATIONAL STUDY OF THE AMERICAN AND EUROPEAN NETWORK OF ANTISYNTHETASE SYNDROME (AENEAS) 107
EARLY DISCONTINUATION OF FIRST LINE BIOLOGICAL TREATMENT WITH ETANERCEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS FROM THE ITALIAN GISEA REGISTRY 100
Rheumatoid Arthritis from Easy to Complex Disease: From the "2022 GISEA International Symposium" 99
Radiomics to predict the mortality of patients with rheumatoid arthritis-associated interstitial lung disease: A proof-of-concept study 98
Rheumatoid arthritis extra-articular lung disease: new insights on pathogenesis and experimental drugs 95
Efficacy and safety of mepolizumab in eosinophilic granulomatosis with polyangiitis: Insights from real-life cases and literature analysis 92
PREDICTION OF LONG-TERM EVOLUTIONARY PROFILES IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (CHURG-STRAUSS) BASED ON BASELINE AND FOLLOW-UP CHARACTERISTICS 92
HARNESSING THE POWER OF RADIOMICS TO PREDICT SURVIVAL IN PATIENTS WITH RA-ILD 91
Totale 21.548
Categoria #
all - tutte 91.071
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 91.071


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.747 144 106 111 99 91 137 81 91 209 173 321 184
2022/20231.874 211 178 145 138 211 215 87 207 230 47 115 90
2023/20241.590 68 89 75 232 219 125 129 254 47 54 123 175
2024/20254.678 143 69 108 319 961 737 396 205 489 174 451 626
2025/20268.095 533 368 640 920 975 599 1.041 390 882 682 584 481
2026/2027141 141 0 0 0 0 0 0 0 0 0 0 0
Totale 21.949